Expensify Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Expensify Inc trades at $2.37 (market cap $208.82M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.4 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 10.9× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| EXFY | SLS | |
|---|---|---|
Market Cap | $208.82M | $2.27B |
Volume | 456,102 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $2.72 | $15.46 |
52-Week Low | $0.75 | $1.39 |
Typical Hold Time | 41 Days | — |
Enterprise Value | $148.44M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.
The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →